Sicart Associates’s PTC Therapeutics PTCT Stock Holding History

Sicart Associates’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,745	Closed	-$224K	–	77
2026 Q2	$224K	Buy	+2,745	New	+$198K	0.05%	72
2026 Q1	–	Sell	-2,745	Closed	-$209K	–	77
2025 Q4	$209K	Buy	+2,745	New	+$199K	0.06%	73
2023 Q3	–	Sell	-5,100	Closed	-$207K	–	68
2023 Q2	$207K	Sell	5,100 -3,075	-38%	-$150K	0.08%	63
2023 Q1	$396K	Hold	8,175	–	–	0.15%	53
2022 Q4	$312K	Hold	8,175	–	–	0.11%	63
2022 Q3	$410K	Hold	8,175	–	–	0.15%	56
2022 Q2	$327K	Hold	8,175	–	–	0.1%	60
2022 Q1	$305K	Hold	8,175	–	–	0.08%	72
2021 Q4	$328K	Hold	8,175	–	–	0.09%	78
2021 Q3	$304K	Hold	8,175	–	–	0.08%	86
2021 Q2	$346K	Hold	8,175	–	–	0.08%	86
2021 Q1	$387K	Sell	8,175 -25	-0.3%	-$1.48K	0.1%	76
2020 Q4	$500K	Hold	8,200	–	–	0.12%	73
2020 Q3	$383K	Hold	8,200	–	–	0.11%	76
2020 Q2	$416K	Hold	8,200	–	–	0.13%	72
2020 Q1	$366K	Sell	8,200 -525	-6%	-$26.4K	0.14%	67
2019 Q4	$419K	Hold	8,725	–	–	0.14%	75
2019 Q3	$295K	Buy	8,725 +550	+7%	+$23.9K	0.1%	87
2019 Q2	$368K	Hold	8,175	–	–	0.15%	67
2019 Q1	$308K	Hold	8,175	–	–	0.13%	70
2018 Q4	$281K	Hold	8,175	–	–	0.14%	72
2018 Q3	$384K	Hold	8,175	–	–	0.18%	66
2018 Q2	$276K	Hold	8,175	–	–	0.14%	77
2018 Q1	$221K	Buy	+8,175	New	+$207K	0.13%	84
2017 Q1	–	Sell	-431,135	Closed	-$4.7M	–	100
2016 Q4	$4.7M	Buy	+431,135	New	+$4.52M	3.25%	5

Other funds holding PTCT

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Sicart Associates's PTCT Position: Q3 2026 in Review

Sicart Associates sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 2,745 shares — an estimated $224K sold.

Sicart Associates first reported a position in PTCT in Q4 2016 and held it in 25 quarters. The position peaked at $4.7M in Q4 2016. 83 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Sicart Associates reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
Sicart Associates sold 2,745 PTC Therapeutics shares in Q3 2026, an estimated $224K.
Sicart Associates first reported a position in PTC Therapeutics in Q4 2016 and held it in 25 quarters.
Sicart Associates's PTC Therapeutics position peaked at $4.7M in Q4 2016.
83 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Sicart Associates's 13F filing for Q3 2026, filed 29 Oct 2026.